US FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Over the last decade, there has been tremendous progress in the treatment of patients with gynecologic cancers with a changing therapy landscape. This summary provides an overview of U.S. Food and Drug Administration (FDA) approvals for gynecologic cancers from 2010 to 2020, totaling 17 new indications. For each of the approved indications, endpoints, trial design, results, and regulatory considerations are outlined. Among these 17 indications, six received accelerated approval (AA) and 11 received regular approval (RA). As of September 2021, of the six AA, three have subsequently demonstrated clinical benefit resulting in conversion to RA and the remaining three have ongoing clinical trials that have not yet reported results. Approval decisions for these 17 indications were supported by primary efficacy endpoints of progression-free survival (n = 10), objective response rate (n = 6), and overall survival (n = 1) and showed a favorable benefit-risk profile. Among the 17 indications, 15 received priority review and three applications participated in one or more novel Oncology Center of Excellence initiatives, including Real Time Oncology Review, Assessment Aid, and Project Orbis. Current FDA thinking on drug development opportunities and regulatory initiatives currently under way will be discussed.

Automated summary

There has been significant progress in the treatment of gynecologic cancers over the past decade. This article summarizes the FDA approvals for gynecologic cancer treatments from 2010 to 2020, totaling 17 new indications. Six of these indications received accelerated approval, while 11 received regular approval. The approval decisions were supported by primary efficacy endpoints and showed a favorable benefit-risk profile. The article also discusses the current FDA thinking on drug development opportunities and regulatory initiatives.